RED BANK, N.J., Dec. 21, 2020 /PRNewswire/ -- Provention
Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to
intercepting and preventing immune-mediated disease, today
announced that it has been added to the NASDAQ Biotechnology Index
(Nasdaq: NBI), effective prior to market open today.
The NASDAQ Biotechnology Index is designed to track the
performance of a set of securities listed on The Nasdaq Stock
Market® (NASDAQ®) that are classified as
either biotechnology or pharmaceutical according to the Industry
Classification Benchmark (ICB). The NASDAQ Biotechnology Index is
re-ranked annually. All securities in the index are listed on the
NASDAQ Global Market or the NASDAQ Global Select Market and meet
minimum market value and share volume requirements, among other
criteria.
The NASDAQ Biotechnology Index forms the basis for a number of
Exchange Traded Funds (ETFs), including the iShares NASDAQ
Biotechnology ETF (Nasdaq: IBB). More information about the
Index can be found at www.nasdaq.com.
About Provention Bio, Inc.:
Provention Bio, Inc.
(Nasdaq: PRVB) is a biopharmaceutical company focused on advancing
the development of investigational therapies that may intercept and
prevent debilitating and life-threatening immune-mediated disease.
The Company has submitted a Biologics License Alliance (BLA)
to the FDA for its lead investigational drug candidate, teplizumab,
for the delay or prevention of clinical type 1 diabetes in at-risk
individuals. The Company's pipeline includes additional
clinical-stage product candidates that have demonstrated in
pre-clinical or clinical studies proof-of-mechanism and/or
proof-of-concept in other autoimmune diseases, including celiac
disease and lupus. Visit www.ProventionBio.com for more
information and follow us on Twitter: @ProventionBio.
Internet Posting of Information:
Provention Bio, Inc.
uses its website, www.proventionbio.com, as a means of
disclosing material nonpublic information and for complying with
its disclosure obligations under Regulation FD. Such disclosures
will be included on the Company's website in the "News" section.
Accordingly, investors should monitor this portion of the Company's
website, in addition to following its press
releases, SEC filings and public conference calls and
webcasts.
Investor Contact:
Sam
Martin, Argot Partners
sam@argotpartners.com
212-600-1902
Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-announces-addition-to-nasdaq-biotechnology-index-301196521.html
SOURCE Provention Bio, Inc.